Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $16.80.

Several research analysts recently issued reports on the company. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research note on Monday, September 16th. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $12.50 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The firm’s 50-day simple moving average is $11.33 and its 200 day simple moving average is $9.40. The stock has a market cap of $854 million, a price-to-earnings ratio of -3.82 and a beta of 1.19. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $12.97.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.80% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

Institutional investors have recently modified their holdings of the business. Quest Partners LLC grew its holdings in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares in the last quarter. Algert Global LLC lifted its stake in Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares in the last quarter. Creative Planning boosted its holdings in Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.